Sprout Health Review (2026): the longevity-stack GLP-1 telehealth

What is Sprout Health?

Sprout Health is a US telehealth platform that connects users with licensed clinicians to prescribe compounded GLP-1 medications — primarily semaglutide and tirzepatide — for weight management. So far, that's the same elevator pitch as every other GLP-1 telehealth shop. Where Sprout is different is the adjacent product line.

Sprout runs a separate longevity catalog that includes NAD+ peptide therapy, BPC-157, and metabolic-support compounds. Users can subscribe to GLP-1 alone, NAD+ alone, or stack both on the same account with a bundle discount. The platform's positioning is explicit: this is for the "wellness optimizer" — someone who's already buying creatine, magnesium glycinate, and a continuous glucose monitor on Amazon, and would rather get the prescription stack from one telehealth provider than four.

That positioning is rare in 2026. Most GLP-1 telehealth shops are single-product subscriptions — they want to be Eden, SkinnyRx, or GobyMeds, and they compete on price or speed. Sprout is competing on stack depth instead, which makes the comparison set different.

The NAD+ stack angle, explained without hype

NAD+ — nicotinamide adenine dinucleotide — is a coenzyme present in every cell of your body. It participates in hundreds of metabolic reactions, particularly the ones that turn food into ATP (cellular energy). NAD+ levels decline with age. That much is uncontroversial biochemistry, well-documented in peer-reviewed metabolism literature.

What is controversial — and where you should keep your skeptic hat on — is how much of a difference exogenous NAD+ supplementation actually makes in a typical adult. Human clinical evidence on injectable NAD+ for "longevity" or "energy" is still thin compared to the marketing volume. There are mechanistic studies, animal studies, and small-cohort human studies; there is not yet a large randomized controlled trial showing that injected NAD+ extends life or measurably reverses aging biomarkers in healthy adults.

We're flagging that openly because Sprout Health, like every NAD+ provider in this category, lives downstream of a wellness narrative that has run ahead of the published evidence. The product is legal. Clinicians prescribe it. Users report subjective improvements in energy. Whether those improvements are pharmacological, placebo, or some combination of the two is something a future trial will have to answer.

Our honest read: if you've already decided you want to try NAD+, Sprout is one of the more transparent platforms to get it from — they don't promise miracles, they don't have an FDA enforcement history, and bundling it with your GLP-1 prescription saves you a separate provider intake. If you haven't decided whether NAD+ is for you, please do not let our review be the deciding factor. Talk to a clinician who can look at your full health picture.

Sprout Health pricing breakdown (2026)

Prices as of May 2026, sourced from public Sprout Health landing pages. Subject to change. Initial intake fees may apply on month 1. Confirm on the Sprout site before paying.

The honest take on cost: Sprout is roughly $50/month more expensive than the cheapest standalone GLP-1 providers (Eden Health at ~$196, SkinnyRx at $199). You're paying for the option to add NAD+ from the same provider. If you're never going to use the longevity add-ons, you're overpaying.

Who Sprout Health is for (and who should skip)

How to qualify for Sprout Health

Sprout uses the same standard intake model as the rest of the category: an online medical questionnaire, ID verification, and a clinician review. There is no in-person visit, no lab draw required on most plans, and no insurance involvement — it's a cash-pay telehealth.

Standard eligibility signals for GLP-1:

• BMI in the range typically considered for weight management treatment (the clinician determines clinical appropriateness)
• No history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
• Not pregnant or planning pregnancy in the near term
• Disclosure of current medications, allergies, and medical conditions

The NAD+ intake is a separate questionnaire and a separate clinician consult — it doesn't auto-piggyback on your GLP-1 approval. Expect 24-72 hours for the GLP-1 decision, similar for NAD+. Shipping typically lands in 5-10 business days from a 503A compounding pharmacy partner.

What month 1 looks like on Sprout

1. Day 1: Intake form (15-20 minutes). Upload ID. Submit medical history.
2. Day 2-3: Clinician reviews. Approval (or request for additional info).
3. Day 3-4: Payment processed. Prescription sent to the 503A partner pharmacy.
4. Day 7-10: Medication arrives in temperature-controlled packaging. Vials, syringes, and dose-escalation instructions included.
5. Week 2: First injection (lowest starting dose). Most users notice early appetite changes within 7-10 days.
6. Week 3-4: Side-effect window — nausea is the most common, usually mild. Sprout's clinician messaging is available for dose-pause guidance.
7. Week 4: Auto-refill triggers for month 2 unless paused. Dose escalation typically begins month 2 per the clinician's plan.

If you added NAD+ at signup, the NAD+ kit ships separately and on its own cadence. The two product lines are billed and shipped independently even when bundled.

The NAD+ science (educational, no claims)

A quick, sober overview of what's actually established in the literature about NAD+, so you can make an informed decision rather than relying on Sprout's marketing copy alone:

What's well-established: NAD+ is essential for mitochondrial energy production, DNA repair, and sirtuin enzyme activity. Tissue NAD+ levels do decline with age in humans (multiple studies). NAD+ precursors (NR, NMN) raise blood NAD+ levels in healthy adults (small RCTs).

What's still unclear: Whether raising NAD+ via exogenous supplementation translates into measurable functional benefits in healthy adults — energy, cognition, longevity biomarkers — at scale. Most positive findings come from animal models or small short-duration human studies. The largest, longest randomized trials we'd want have not yet been published as of mid-2026.

Safety profile: Injectable NAD+ has a generally favorable short-term safety record in clinical settings. Flushing, mild discomfort at injection site, and transient nausea are the most reported. Long-term safety in healthy adult populations is less studied than short-term safety.

This is the picture as it actually exists in the literature in May 2026. Sprout Health does not have to defend the science — they are simply providing access to a legal compounded product that licensed clinicians can prescribe. Whether you should be the consumer is a decision for you and your clinician.

Sprout Health FAQ

Final verdict

FTC disclosure: We earn a commission when you sign up through our links, at no extra cost to you. This does not influence our editorial assessment.

See Current Sprout Pricing →